Management of chronic hepatitis B with Unani Formulation

Clinical evaluation of Qust (Saussurea lappa) And Afsanteen (Artemisia absinthium) in The Management of Chronic Hepatitis B on Immunological Parameters

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/08/009212

Enrollment

Registered

2017-08-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K732- Chronic active hepatitis, not elsewhere classified Health Condition 2: null- Chronic Hepatitis B

Interventions

Intervention1: Sassurea Lappa and Artemesia absinthium: Dried decoction in capsules 7 g of each once daily for 12 weeks Control Intervention1: Tenofovir tablet: 300 mg once daily for 12 weeks

Eligibility

Inclusion criteria

Inclusion criteria: Clinically stable patients with HBV positive history Patients of all genders HBsAg positive cases with clinical history of more than six months Patients with HBV DNA quantitative greater than 2000 IU/mL ALT > 2 times of upper limit of normal Anti HBc positive in case of suspected cases of chronic hepatitis B Both HBeAg positive and negative patients Raised Bilirubin

Exclusion criteria

Exclusion criteria: Pregnant women and lactating mothers Patients who failed to give informed consent Cirrhosis and portal hypertension/ascites Patients with heart and kidney disease

Design outcomes

Primary

Measure	Time frame
HBsAg, HBeAg, HBV DNA, Anti HBs, Anti HBe USG W/ATimepoint: 0 day, 84th day	—

Secondary

Measure	Time frame
CBC, LFT, ESR, KFT, Blood Sugar F & PP, Urine R/M, PT/INRTimepoint: 0 day, 14th day, 42nd day,84th day	—

Countries

India

Contacts

Public ContactDr Umar Jahangir

Jamia Hamdard

drmasjh@rediffmail.com9891273627

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026